Immunoglobulin News and Research

RSS

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

Only half of pregnant women worldwide get treatment for preventable Rh disease

Only half of pregnant women worldwide who need a treatment developed over 50 years ago to prevent Rh disease--an often-fatal condition in fetuses and newborns that is now exceedingly rare in the United States and Western Europe--actually receive it, finds a study led by researchers at Vagelos College of Physicians and Surgeons at Columbia University Irving Medical Center.

10 Aug 2020

Evidence for antibody longevity in COVID-19 patients

A study led by researchers at the University of Toronto, Canada, has found evidence that immunoglobulin G (IgG) antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are sustained for at least three months.

5 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Pre-COVID-19 coronavirus antibodies fail to neutralize SARS-CoV-2

Researchers in Austria have shown that antibodies with potent neutralizing activity against a well-established seasonal coronavirus had no neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2020

Study finds synthetic neutralizing/enhancing antibodies to SARS-CoV-2

A new study published on the preprint server bioRxiv in July 2020 reports the discovery of some antibody molecules that have powerful enhancing or neutralizing activity against the virus, in a library of synthetic antibodies. These hold the promise of being useful for the prevention or treatment of this illness.

30 Jul 2020

Basigin/CD147 discarded as an accessory SARS-CoV-2 binding receptor

By using specialized assays customized to detect specific receptor interactions, researchers from the Wellcome Sanger Institute in Cambridge UK find no evidence for direct binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to a transmembrane glycoprotein known as basigin.

28 Jul 2020

Common antioxidant enzyme catalase as COVID-19 treatment

A new paper by researchers from the USA and China and published on the preprint server bioRxiv in July 2020 discusses a new drug based on the catalase enzyme, which could play a vital part in reducing the inflammation associated with progressive and severe COVID-19 disease.

17 Jul 2020

Antibodies to SARS-CoV-2 disappear within three months

The question is, does this infection confer lasting immunity? A new study published in the journal Clinical Microbiology and Infection in July 2020 appears to show that it does not, with antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disappearing within three months of infection.

15 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

Serology distinguishes children with MIS-C associated with COVID-19

Researchers in the United States say that measuring antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may help to distinguish between multisystem inflammatory syndrome in children (MIS-C) and other clinically similar syndromes.

13 Jul 2020

Novel antibody test for SARS-CoV-2

A team of researchers in the United States have developed highly specific and sensitive assays that could improve understanding of the antibody response in coronavirus disease 2019 (COVID-19) and help to determine the effectiveness of vaccines.

9 Jul 2020

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.

7 Jul 2020

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

A study conducted by German researchers has shown that the neurological symptoms observed in some patients with coronavirus disease 2019 (COVID-19) may be caused by autoantibodies targeting the brain.

7 Jul 2020

Potential new biomarker could improve COVID-19 diagnosis

Researchers at Montpellier University Hospital have discovered that an interferon-inducible receptor expressed on monocytes could be a useful biomarker for the rapid triaging of patients suspected to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

30 Jun 2020

Chemically engineered peptides could help fight persistent human health challenges

Chemically engineered peptides, designed and developed by a team of researchers at Rensselaer Polytechnic Institute, could prove valuable in the battle against some of the most persistent human health challenges.

26 Jun 2020

Antibody tests may give false hope of immunity, health experts warn

Amid the coronavirus pandemic, health experts warn against the use of antibody tests to determine if a person has immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An antibody test determines if a person developed antibodies against the infection due to past exposure.

26 Jun 2020

Immune response variations across the COVID-19 spectrum

A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.

25 Jun 2020

Scientists find COVID-19 antibodies fade quickly

Now, a new study shows that the levels of antibodies found in recovered coronavirus disease (COVID-19) patients declined sharply in just two to three months after infection for both symptomatic and asymptomatic patients.

23 Jun 2020